Synthesis, crystal, electronic studies, in silico modelling, and ADMET profiling of (E)-5-(diethylamino)-2-(((1,3-diphenyl-1H-pyrazol-5-yl)imino)methyl)phenol (DDPMP): a promising anti-cancer agent

A pyrazole-based imine compound, DDPMP , has been designed using an efficient and simple method. The synthesised compound has been crystallised, and its structure has been confirmed using several techniques, including FTIR, 1 H and 13 C NMR, DEPT-135, H-H COSY, HSQC, and HMBC. The mass of the compound was verified through high-resolution mass spectrometry (HRMS), and both absorption and emission spectra were recorded. Solvatochromism studies reveal that DDPMP exhibits a bathochromic shift. Geometrical optimisation and an analysis of the electronic properties, along with electrostatic potential mapping, were performed using Density Functional Theory (DFT) and Time-Dependent DFT (TD-DFT). Furthermore, DDPMP demonstrates excellent anticancer activity, as confirmed through in-silico studies that compared it with three PDB structures: 1SA0, 5XIW, and 4O2B. Consequently, DDPMP serves as a promising tubulin inhibitor. • Synthesis and spectroscopic confirmation of (E)-5-(diethylamino)-2-(((1,3-diphenyl-1H-pyrazol-5-yl)imino)methyl)phenol (DDPMP), via a conventional method. • The structural verification of DDPMP was conducted using various NMR techniques along with the single-crystal XRD. • DFT calculations were performed to analyse spectral properties, energy differences between the excited states, and electron density. • In-silico tests with PDB structures: 1SA0, 5XIW, and 4O2B assessed the binding affinity of the DDPMP as a promising tubulin inhibitor. • In silico studies reveal DDPMP can serve as an excellent anticancer agent.